Bio-Rad Laboratories, Inc.
BIO
$265.26
$0.940.36%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 396.56% | 108.94% | -209.59% | 130.16% | -664.08% |
| Total Depreciation and Amortization | 6.56% | -2.81% | 0.77% | 6.87% | -1.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,918.99% | -101.55% | 235.72% | -125.78% | 817.23% |
| Change in Net Operating Assets | 76.83% | 120.19% | -197.87% | 132.48% | -1,358.33% |
| Cash from Operations | -10.32% | 4.59% | -24.07% | 67.58% | 39.83% |
| Capital Expenditure | -32.85% | 19.84% | -6.67% | 4.90% | -5.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -185.96% | -43.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 293.83% | 200.35% | 180.31% | -236.85% | 489.66% |
| Cash from Investing | -4,079.31% | 109.49% | 45.10% | -80.05% | 28.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.00% | -143.90% | 66.67% | -23.00% | 50.00% |
| Issuance of Common Stock | -2.33% | 9.97% | -23.36% | 8.55% | -14.55% |
| Repurchase of Common Stock | -37.68% | -75,944.78% | 99.87% | 0.23% | -2,053.19% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -39.51% | -272.22% | 72.65% | 0.64% | -- |
| Foreign Exchange rate Adjustments | -800.00% | -117.61% | 236.01% | -297.76% | 40.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -200.00% | -- | -- |
| Net Change in Cash | -554.65% | -57.08% | 1,634.43% | 117.14% | -188.78% |